This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Next Line of Targeted Drugs for CML Shows Promise

Tracy Hampton, PhD

JAMA. 2006;295:369-370.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Atlanta—Promising results from a trial of imatinib for the treatment of chronic myeloid leukemia (CML) created a stir 6 years ago at the annual meeting of the American Society of Hematology as a validation of the notion that tailoring drugs to act on a specific molecular target could destroy malignant cells while sparing normal ones (Stephenson J. JAMA. 2000;283:317-321). Now, at the society's annual meeting, held here in December, researchers announced encouraging findings on the next generation of imatinib-related drugs.

"This is very, very good news for patients with CML," said Brian Druker, MD, of the Oregon Health & Science University Cancer Institute, in Portland, who led the initial study of imatinib. "It is also useful as a paradigm for targeted therapies, understanding resistance, and bringing new drugs into the clinic based on mechanisms of resistance," he added.

Chronic myeloid leukemia is caused by a swap . . . [Full Text of this Article]

NEED FOR IMPROVEMENT



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys
Christopher et al.
Drug Metab. Dispos. 2008;36:1341-1356.
ABSTRACT | FULL TEXT  

Farnesyl transferase inhibitor resistance probed by target mutagenesis
Raz et al.
Blood 2007;110:2102-2109.
ABSTRACT | FULL TEXT  

The Emerging Market Dynamics Of Targeted Therapeutics
Calfee and DuPre
Health Aff (Millwood) 2006;25:1302-1308.
ABSTRACT | FULL TEXT  

New Assignments for Multitasking Signal Transduction Inhibitors
Zhang and Meier
Mol. Pharmacol. 2006;69:1510-1512.
ABSTRACT | FULL TEXT